Tandem Investment Advisors Inc. Sells 409 Shares of Johnson & Johnson (NYSE:JNJ)

Tandem Investment Advisors Inc. cut its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 505,100 shares of the company’s stock after selling 409 shares during the quarter. Johnson & Johnson comprises 3.1% of Tandem Investment Advisors Inc.’s portfolio, making the stock its 17th biggest holding. Tandem Investment Advisors Inc.’s holdings in Johnson & Johnson were worth $81,856,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Portside Wealth Group LLC lifted its position in shares of Johnson & Johnson by 7.0% during the 3rd quarter. Portside Wealth Group LLC now owns 13,429 shares of the company’s stock valued at $2,176,000 after acquiring an additional 879 shares during the period. Keynote Financial Services LLC raised its stake in Johnson & Johnson by 3.7% in the third quarter. Keynote Financial Services LLC now owns 11,332 shares of the company’s stock valued at $1,836,000 after purchasing an additional 408 shares in the last quarter. Western Pacific Wealth Management LP grew its stake in Johnson & Johnson by 19.3% during the third quarter. Western Pacific Wealth Management LP now owns 3,756 shares of the company’s stock worth $609,000 after buying an additional 607 shares in the last quarter. Keudell Morrison Wealth Management increased its holdings in Johnson & Johnson by 10.8% in the 3rd quarter. Keudell Morrison Wealth Management now owns 9,211 shares of the company’s stock valued at $1,493,000 after buying an additional 901 shares during the period. Finally, Droms Strauss Advisors Inc. MO ADV acquired a new position in shares of Johnson & Johnson in the 3rd quarter valued at approximately $201,000. 69.55% of the stock is owned by institutional investors.

Insider Transactions at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the sale, the vice president now directly owns 18,973 shares in the company, valued at $3,131,683.38. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on JNJ. Morgan Stanley lifted their price objective on shares of Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. The Goldman Sachs Group dropped their price objective on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research report on Friday, July 19th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. TD Cowen reduced their price target on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research note on Thursday, July 18th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Seven investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $175.00.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $156.71 on Friday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $168.85. The firm has a market cap of $377.30 billion, a PE ratio of 22.68, a price-to-earnings-growth ratio of 2.81 and a beta of 0.53. The firm’s fifty day moving average is $162.96 and its 200-day moving average is $155.76.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. During the same period in the previous year, the business earned $2.66 EPS. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. Sell-side analysts predict that Johnson & Johnson will post 9.94 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be issued a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 annualized dividend and a yield of 3.17%. Johnson & Johnson’s payout ratio is 71.78%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.